Alignment with FDA obtained on study design to advance two Ph 3 trials in gastroesophageal cancers (FAPI-GO) and PDAC (FAPI-PRO), with [18F] FAPI-74
“The successful FDA engagement brings us closer to making FAPI a reality for patients in areas of unmet need across multiple tumor types”, said Sherly Mosessian, Ph.D., Chief Scientific Officer of SOFIE Biosciences. “Unlike conventional imaging and FDG PET, FAPI targets cancer-associated fibroblasts in the tumor microenvironment, giving us a key target for determination of disease. FAPI PET has tremendous potential in many oncologic and non-oncologic diseases. We are looking forward to focusing our initial efforts on the cancers of the GI tract, specifically gastroesophageal cancers and PDAC, where we see tremendous unmet need that can be successfully addressed with FAPI PET. We are excited to advance into Phase 3 and continue building the evidence that will establish FAPI PET/CT as a transformative tool in precision oncology.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.